Launch of obesity drug will be Novo Nordisk's fastest ever
Novo Nordisk is gearing up for the launch of the firm's recently-approved obesity drug Wegovy. EVP Camilla Sylvest states the product needs to enter the market "as quickly as possible".
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
After receiving approval from the US Food and Drug Administration (FDA) on Friday, Novo Nordisk is already poised to launch its obesity drug Wegovy over the course of this week. Meanwhile, the Danish pharmaceutical company expects the drug will be available in US pharmacies as of June 18.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves Novo Nordisk's semaglutide as obesity treatment
For subscribers
